Register entryShortage reported

Rubicon Research Canada Limited

Data as of · How to read this entry

Registered sites
5
Active NDC listings
0
Live patents
0
Shortage listings
11
Countries
2
Base
India
Authorisation

Registered operations

Analytical testing5Labelling3Finished drug manufacture3Packaging3
Sites

Registered establishments

5
EstablishmentAddressRegistered forFEI / DUNS
Rubicon Research Canada Limited255 Spinnaker Way Unit 6, Concord, Ontario L4K4J1, Canada (CAN)Analytical testing3003285511204343193
Rubicon Research LimitedA-17, ISEZ, Phase II, Sector 3, Pithampur, Dhar, Dhar, Madhya Pradesh 454775, India (IND)Analytical testing, Labelling, Finished drug manufacture, Packaging3016480976771793568
RUBICON RESEARCH LIMITEDRegistrant: Rubicon Research LimitedJ 4/2, ADDITIONAL MIDC, Satara, Maharashtra 415004, India (IND)Analytical testing, Labelling, Finished drug manufacture, Packaging3012953979737796233
Rubicon Research LimitedB-75, Medone House, Road No. 33, Wagale Industrial Estate, Thane, Maharashtra 400604, India (IND)Analytical testing3006559899918629544
Rubicon Research LimitedPlot No K-30/4 & K30/5, MIDC, Additional Ambernath Area,, Thane, Maharashtra 421 506, India (IND)Analytical testing, Labelling, Finished drug manufacture, Packaging3008252295677604197
Alert

Drug shortage listings

11
DrugPresentationStatusAvailabilityPosted / updated
Clonazepam TabletNeurology, Pediatric, PsychiatryClonazepam, Tablet, .5 mg (NDC 72888-152-00)CurrentAvailable10 Mar 20231 Jun 2026
Clonazepam TabletNeurology, Pediatric, PsychiatryClonazepam, Tablet, 2 mg (NDC 72888-154-05)CurrentAvailable10 Mar 20231 Jun 2026
Clonazepam TabletNeurology, Pediatric, PsychiatryClonazepam, Tablet, .5 mg (NDC 72888-152-30)CurrentAvailable10 Mar 20231 Jun 2026
Clonazepam TabletNeurology, Pediatric, PsychiatryClonazepam, Tablet, 1 mg (NDC 72888-153-00)CurrentAvailable10 Mar 20231 Jun 2026
Clonazepam TabletNeurology, Pediatric, PsychiatryClonazepam, Tablet, 1 mg (NDC 72888-153-05)CurrentAvailable10 Mar 20231 Jun 2026
Clonazepam TabletNeurology, Pediatric, PsychiatryClonazepam, Tablet, 1 mg (NDC 72888-153-30)CurrentAvailable10 Mar 20231 Jun 2026
Clonazepam TabletNeurology, Pediatric, PsychiatryClonazepam, Tablet, 2 mg (NDC 72888-154-30)CurrentAvailable10 Mar 20231 Jun 2026
Clonazepam TabletNeurology, Pediatric, PsychiatryClonazepam, Tablet, 1 mg (NDC 72888-153-01)CurrentAvailable27 Mar 20231 Jun 2026
Clonazepam TabletNeurology, Pediatric, PsychiatryClonazepam, Tablet, .5 mg (NDC 72888-152-01)CurrentAvailable10 Mar 20231 Jun 2026
Clonazepam TabletNeurology, Pediatric, PsychiatryClonazepam, Tablet, 2 mg (NDC 72888-154-01)CurrentAvailable10 Mar 20231 Jun 2026
Clonazepam TabletNeurology, Pediatric, PsychiatryClonazepam, Tablet, .5 mg (NDC 72888-152-05)CurrentAvailable10 Mar 20231 Jun 2026
Neighbours

Registered in the same town

12
Compare

Comparable companies in India

Enquiry

Common questions

Is Rubicon Research Canada Limited FDA approved?
Rubicon Research Canada Limited holds 5 FDA-registered establishments across 2 countries. Registration puts a site on the FDA's register and open to inspection; it is not an approval of the company. Approvals attach to individual drug applications.
Where are Rubicon Research Canada Limited's drugs manufactured?
At registered sites in Canada, India. The FDA register lists Concord; Dhar; Satara; Thane. Registered operations: analytical testing, labelling, finished drug manufacture, packaging.
Are any Rubicon Research Canada Limited products in shortage?
11 presentations are currently listed in the FDA drug shortage database under Rubicon Research Canada Limited, covering Clonazepam Tablet.

Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.